Your browser doesn't support javascript.
loading
LncRNA SNHG1 exerts a protective role in cardiomyocytes hypertrophy via targeting miR-15a-5p/HMGA1 axis.
Yan, Si-Min; Li, Hu; Shu, Qing; Wu, Wei-Jun; Luo, Xue-Mei; Lu, Lei.
Afiliação
  • Yan SM; Division of Clinical Pharmacy, Department of Pharmacy, Drum Tower Hospital Affiliated to Medical School of Nanjing University, 321 Zhong Shan Road, Nanjing, Jiangsu, 210000, China.
  • Li H; Department of Cardiology, Drum Tower Hospital Affiliated to Medical School of Nanjing University, 321 Zhong Shan Road, Nanjing, Jiangsu, 210000, China.
  • Shu Q; Division of Clinical Pharmacy, Department of Pharmacy, Drum Tower Hospital Affiliated to Medical School of Nanjing University, 321 Zhong Shan Road, Nanjing, Jiangsu, 210000, China.
  • Wu WJ; Division of Clinical Pharmacy, Department of Pharmacy, Drum Tower Hospital Affiliated to Medical School of Nanjing University, 321 Zhong Shan Road, Nanjing, Jiangsu, 210000, China.
  • Luo XM; Division of Clinical Pharmacy, Department of Pharmacy, Drum Tower Hospital Affiliated to Medical School of Nanjing University, 321 Zhong Shan Road, Nanjing, Jiangsu, 210000, China.
  • Lu L; Department of Cardiology, Xuzhou Hospital of Traditional Chinese Medicine Affiliated to Medical School of Nanjing University of Traditional Chinese Medicine, 169 Zhong Shan South Road, Xuzhou, Jiangsu, 221000, China.
Cell Biol Int ; 44(4): 1009-1019, 2020 Apr.
Article em En | MEDLINE | ID: mdl-31889385
ABSTRACT
Heart failure preceded by pathological cardiac hypertrophy is a leading cause of death. Long noncoding RNA small nucleolar RNA host gene 1 (SNHG1) was reported to inhibit cardiomyocytes apoptosis, but the role and underlying mechanism of SNHG1 in pathological cardiac hypertrophy have not yet been understood. This study was designed to investigate the role and molecular mechanism of SNHG1 in regulating cardiac hypertrophy. We found that SNHG1 was upregulated during cardiac hypertrophy both in vivo (transverse aortic constriction treatment) and in vitro (phenylephrine [PE] treatment). SNHG1 overexpression attenuated the cardiomyocytes hypertrophy induced by PE, while SNHG1 inhibition promoted hypertrophic response of cardiomyocytes. Furthermore, SNHG1 and high-mobility group AT-hook 1 (HMGA1) were confirmed to be targets of miR-15a-5p. SNHG1 promoted HMGA1 expression by sponging miR-15a-5p, eventually attenuating cardiomyocytes hypertrophy. There data revealed a novel protective mechanism of SNHG1 in cardiomyocytes hypertrophy. Thus, targeting of SNHG1-related pathway may be therapeutically harnessed to treat cardiac hypertrophy.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Cardiomegalia / Proteínas HMGA / Miócitos Cardíacos / MicroRNAs / RNA Longo não Codificante Limite: Animals Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Cardiomegalia / Proteínas HMGA / Miócitos Cardíacos / MicroRNAs / RNA Longo não Codificante Limite: Animals Idioma: En Ano de publicação: 2020 Tipo de documento: Article